

For anemia associated with chronic kidney disease



Aranesp® should be dosed less frequently than Epoetin alfa¹

Converting from Epoetin alfa TIW to Aranesp® QW

Previous Weekly Epoetin alfa Dose (units/week)	Weekly Aranesp® Dose (mcg/week)
11,000 to 17,999	40
18,000 to 33,999	60
34,000 to 89,999	100
≥ 90,000	200

Example: If you currently administer 3,500 units of Epoetin alfa TIW (10,500 units per week), give 25 mcg of Aranesp® QW.

- Determine the total 1-week dose of Epoetin alfa.
- Refer to the above chart to determine the appropriate starting Aranesp® QW dose.
- Available in six convenient Aranesp® SingleJect® prefilled syringe and vial strengths: 25 mcg, 40 mcg, 60 mcg, 100 mcg, 150 mcg, and 200 mcg.

Aranesp® is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients either on or not on dialysis.

Recommended starting dose for new patients is 0.45 mcg/kg/wk (SC or IV). Aranesp® should be administered QW if a patient was receiving Epoetin alfa BIW or TIW. Please refer to the Dosage and Administration section of the Aranesp® package insert for complete conversion information.

Please also refer to the accompanying Aranesp® package insert for full prescribing information.

1. Aranesp® (darbepoetin alfa) prescribing information, Amgen.

AMGEN

Amgen
One Amgen Center Drive
Bovine, CA 94626
www.amgen.com



Aranesp®
(darbepoetin alfa)

For anemia associated with chronic kidney disease



Aranesp® should be dosed less frequently than Epoetin alfa¹

Converting from Epoetin alfa QW to Aranesp® Q2W

Cumulative 2-Week Epoetin alfa QW Dose (units)	Q2W Aranesp® Dose (mcg)
5,000 to 10,999	25
11,000 to 17,999	40
18,000 to 33,999	60
34,000 to 89,999	100
≥ 90,000	200

Example: If you currently administer 10,000 units of Epoetin alfa QW, you would double this amount (20,000 units) to determine the appropriate Aranesp® Q2W dose. In this example, 60 mcg of Aranesp® would be given Q2W.

- Determine the weekly dose of Epoetin alfa and multiply by 2.
- Refer to the above chart to determine the appropriate starting Aranesp® Q2W dose.
- Titrate as necessary to maintain a target hemoglobin (Hb) not to exceed 12 g/dL.

Aranesp® is contraindicated in patients with uncontrolled hypertension. Increases in hemoglobin greater than approximately 1.0 g/dL during any 2-week period have been associated with serious side effects. The most commonly reported side effects in Aranesp® trials were infection, hypertension, hypotension, myalgia, headache, and diarrhea.

Amgen's Medical Information Connection™ is available to answer medical, clinical, or other questions regarding Amgen products.

Call or visit us on the Web:

1-800-77-AMGEN (1-800-772-6436)

(Monday through Friday,
10 AM to 7 PM ET)

www.amgenmedinfo.com
www.aranesp.com



Aranesp®
(darbepoetin alfa)